







































Apoptosis is an evolutionary conserved program that 
leads to cell death. Apoptotic cell death plays a role in 
normal development (e.g. - embryogenesis, morpho-
genesis) and in maintaining adult homeostasis (e.g. - 
immune response resolution, tissue remodeling, 
elimination of damaged/dysfunctional cells) [1, 2]. The 
physical manifestations of aging reflect a loss of 
homeostasis that effects molecular, cellular and organ 
system functional capacity. As a sentinel homeostatic 
pathway, changes in apoptosis can have patho-
physiological consequences in aging. For example, too 
much apoptosis can yield tissue degeneration [3-6], 
while too little apoptosis allows either dysfunctional 









































































cytochrome  c  regardless  of  age.  These  markers  correlated  with  disease  severity  consistent  with  tumor  subversion  of




persist [7-9]. Thus, cellular maintenance protocols 
involve a delicate balance in pro- and anti-apoptotic 
factors/signals. 
 
Fas is a cell-surface receptor that transduces apoptotic 
signals from another cell-surface receptor Fas ligand, 
FasL [10, 11]. Fas and FasL have also been observed as 
soluble molecules. Soluble Fas arises from alternatively 
spliced mRNA (9, 10) and all variants of sFas inhibit 
apoptosis induced by FasL [12, 13]. FasL can undergo 
proteolytic cleavage to liberate a 26 kDa soluble form 
of the molecule [14]. The physiological role of sFasL in 
the regulation of apoptosis remains unclear as both 
stimulatory [15, 16] and inhibitory [17, 18] activity has 
been reported. Cytochrome c has a well defined role in 
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though it was recently shown that cytochrome c exists 
in a complex in serum with leucine-rich alpha-2-
glycoprotein-1 which altered immunoreactivity [20]. In 
order to assess the global balance of systemic markers 
of apoptosis, we developed an immunoassay to measure 
total serum levels of cytochrome c and determined the 
distribution and levels of sFas, sFasL and total 
cytochrome c in serum from a large clinically defined 
normal group. In addition, we used the same surrogate 
markers of apoptosis to characterize their levels in a 
group well characterized as having altered apoptosis 




We determined serum levels of sFas in 204 normal sub-
jects. For all subjects, values for fasting glucose, thyroid 





































The mean value for sFas was 4107 ± 1352 pg/ml. When 
the frequency distribution of serum values was analyzed 
by histogram, a slight hook at the high end was evident 
(Figure 1a). The results were stratified by gender to 
further study the distribution. For the samples obtained 
from the 94 female donors, the mean donor age was 53 
and ranged from 21 to 87, while for the 110 male donors, 
the mean age was 52 and ranged from 22 to 88. Serum 
levels of sFas were significantly higher in males than in 
females, comparing by a Mann Whitney test (Figure 1b 
and Table I). Mean BMI values were 22.6 ± 1.4 and 22.1 
± 1.6 kg/m2 for women and men, respectively. The 
difference by gender in sFas levels was still significant 
after controlling for BMI. When sFas levels were plotted 
versus the age of the subject, the reason for the high-end 
hook to the distribution of normal values became 
apparent. Both genders exhibited an age-dependent 












































































The serum levels of sFasL were determined in the same 
subjects. The mean value for sFasL was 92.8 ± 21.5 
pg/ml. When the distribution of serum values was 
analyzed by histogram, a slight hook at the low end was 
evident (Figure 2a). Again, the results were stratified by 
gender to further study the distribution. Serum levels of 
sFasL were not significantly different between genders 
(Figure 2b and Table I). Plotting sFasL levels versus the 
age of the subject revealed that both genders exhibited 
an age-dependent decrease in sFasL values (Figure 2c 
and d). 
 
While a role for sFas as an anti-apoptotic factor is 
accepted in the literature, the pro-apoptotic role of 
sFasL is more equivocal [15-18]. A third marker for 
apoptosis was developed. Cytochrome c release from 
the mitochondria is a sentinel signal initiating apoptosis 
[21] and serum levels of cyt-c have been used as a 
marker of apoptosis [22, 23]. However, cytochrome c is 
bound to in serum to leucine-rich alpha-2-glycoprotein-
1 which can mask antibody epitopes, potentially 
interfering with immunoassay quantification [20]. We 
























  sFas (pg/ml)  sFasL (pg/ml)  Cytochrome c (µg/ml) 
  female male female male female male 

















chrome c to generate a standard curve and interpolate 
unknown concentrations from serum samples that had 
been denatured and reduced thereby disrupting binding 
complexes and enabling the quantification of total 
cytochrome c levels (Figure 3). 
 
 The mean value for serum levels of total cytochrome c 
was 0.71 ± 0.42 µg/ml. The frequency distribution of 
serum values was analyzed by histogram and a 
nonparametric distribution was evident (Figure 4a). 
When the results were stratified by gender, the 
difference in mean (and median) values by gender were 
not significant (Figure 4b and Table I). Plotting total 
cytochrome c levels versus the age of the subject 
revealed that both genders exhibited an age-dependent 
decrease in total cytochrome c, though the slopes 
appeared to be different (Figure 4c and d). 
 
Because of the nonparametric distribution of these 
apoptotic markers, the association of serum levels with 
donor age was analyzed conservatively by Spearman 
nonparametric correlation (Table I). Significant correla-
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a  p < 0.0001  p = 0.13  p = 0.053 
age r 
b 0.651 0.647  -0.534  -0.337  -0.719  -0.855 
p value 











www.impactaging.com                   654                                              AGING, July    2009, Vol.1 No.7observed. sFas in serum correlated positively with 
increasing age among females, among males and among 
the two combined. In contrast, FasL and total cytochrome 
c correlated negatively with age. Segregating serum 
samples by gender and by decade of life enabled 
statistical comparison of gender values by decade using a 
nonparametric Mann Whitney test. Between the ages of 
41 and 80, females had significantly lower levels of the 
anti-apoptotic marker sFas compared with men (Figure 
5a). The serum levels of the potentially pro-apoptotic 
sFasL, although higher on average in females, were not 
significantly different then those in men over the seven 
decades (Figure 5b).  The apoptosis marker cytochrome c 
exhibited levels that were different between men and 








































The observed shifts in the balance of pro- and anti-
apoptotic factors (sFasL and sFas, respectively) and the 
apoptosis marker (cytochrome c) with age are consistent 
with decreased net apoptosis with increasing age. 
Neoplasm growth and tumor progression rely in part on 
blocking apoptosis [24-26]. Serum from a group of 
women with breast cancer (n = 66) and men with 
prostate cancer (n=38) were analyzed for sFas, sFasL 
and total cytochrome c and the distribution of the values 
compared with age and gender-matched normal values 
(Table II). sFas levels were significantly elevated in 
both breast and prostate cancer. In contrast, sFasL and 
cytochrome c levels were significantly reduced in both 
















































































The association of cancer stage groupings  with 
apoptosis markers was investigated for breast and 
prostate cancer. The breast cancer serum values were 
segregated by stage where stage I is small localized 
tumors with no spreading to axillary lymph nodes; stage 
II disease has larger tumors and potential spread to the 
lymph nodes; stage III disease has spread to other 
lymph nodes or tissues near the breast; while stage IV is 
metastatic cancer. For prostate cancer, stage II cancer is 
localized within the prostate but palpable, stage III 
cancer has broken through the covering of the prostate 
but is still regional, and stage IV cancer has spread to 
other tissues. When the distribution of sFas, sFasL and 
cytochrome c were profiled by stage using Tukey box 
plots, discrete patterns were observed (Figure 6).   
 
Serum sFas levels increased with increasing stages of 
breast cancer (Figure 6a). While stage I disease was not 
significantly different from normal, stages II, III, and IV 
were significantly elevated relative to the normal. The 
more advanced stage III disease was significantly 
elevated compared to normal and earlier stages, and 







































static disease (stage IV) was significantly elevated 
compared with all other stages and had a median value 
~2-fold higher then normal and stage I breast cancer. 
Serum sFas levels in prostate cancer exhibited a similar 
trend of increasing median values with increasing stage. 
However, only stage IV disease was significantly 
different from both normal and stage I disease (Figure 
6b). 
 
Serum sFasL levels in breast cancer decreased with 
increasing stage, with more advanced stages (II, III and 
IV) significantly different from normal and stage I 
(Figure 6c). With prostate cancer, sFasL levels 
decreased significantly between normal and stages II, II 
and IV (Figure 6d). Similarly, serum cytochrome c 
levels were significantly reduced between normal and 
stages I through IV of breast cancer (Figure 6e) and 
between normal and stages II, II and IV of prostate 
cancer (Figure 6f). Thus, subjects with cancer have 
higher anti-apoptotic factors (sFas) in circulation and 
less proapoptotic factors (sFasL, cytochrome c) in 
circulation.  Also, the more advanced the cancer, the 




































Apoptosis, originally believed to be a process with only 
negative effects, now is recognized to balance the 
beneficial potential of eliminating damaged cells against 
the pathological effects of deleterious cell death (e.g. 
neurodegenerative disease) [27]. Failures in apoptosis 
can contribute to the senescent cell phenotype as well as 
rogue cell proliferation [28]. It has been shown that 
apoptosis is an important cellular defense mechanism in 
maintaining genetic stability, and centenarians who 
have aged successfully possess cells that are more prone 
to apoptosis [29]. The major age related disease leading 
to mortality is cardiovascular disease.  Studies have 
shown that apoptotic cell death effect cardiac tissue, and 
in addition, cells that avoid apoptosis participate in the 
progression of atherosclerosis [30, 31]. Cancer, another 
leading cause of mortality, arises from neoplastic 
progression through avoidance of apoptosis [32].  In 
addition, dysregulation of Fas/FasL mediated apoptosis  
can contribute to the pathogenesis of pulmonary [33, 





































Studies with mice having Fas/FasL mutations suggest 
that that a major function of Fas-mediated apoptosis is 
the elimination of activated immune cells from the 
peripheral circulation [37]. Similarly, humans with 
autoimmune lymphoproliferative syndrome have 
mutations in Fas [38, 39]. Maintenance of Fas apoptosis 
signaling is a crucial feature for successful immune 
aging [40]. In young immune fit individuals, stimulation 
of T cells leads to upregulation of Fas, FasL, and 
Fas/FasL engagement-induced apoptosis signaling 
causing cell death which eliminates the majority of T 
cells that are activated in response to a stimulus, thereby 
preventing the accumulation of autoreactive T cells. An 
age-related impairment of Fas/FasL mediated apoptosis 
is believed to contribute to compromised regulation of 
the immune system and immunosenscence [28]. The 
age related shift in favor of reduced apoptosis (higher 
sFas with lower sFasL and total cytochrome c) may 
contribute to reduced clearance of immune cells leading 
to a state of chronic inflammation [27]. A chronic 
inflammatory state may underlie a number of 
pathologies including cancer [41], cardiovascular 
female NL  BCA  male NL  PCA 
n  70 66 40 38 
Age (years)
a  -  62 ± 14  -  66 ± 9 
sFas  (pg/ml)     
mean±SD  3585±918  5202±1732 5023±1309 6249±2324 
median  3490 4831 5038 5587 
range  1603-5877 2651-11990 3048-8026 3462-11580 
U-test
b  p < 0.001  p < 0.05 
sFasL (pg/ml)     
mean±SD  94.4±20.1 75.3±26.2 89.0±19.6 69.7±22.0 
median  97.3 75.2 92.2 62.2 
range  45.9-139.4 15.6-125.0 40.6-130.3 19.4-127.7 
U-test
b  p < 0.0001  p < 0.0001 
Cytochrome c (µg/ml)     
mean±SD  0.673±0.266 0.27±0.14 0.458±0.243 0.23±0.09 
median  0.601 0.24 0.406 0.21 
range  0.239-1.329 0.07-0.74 0.128-1.039  0.09-0.046 
U-test
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osteoporosis [47], rheumatoid arthritis [48], and 
cognitive disorders such as Alzheimers and Parkinson's 
disease [49-51]. It is of note that the pro-inflammatory 
marker interleukin-6 appears to be protective against 
apoptosis [52-55], its serum levels are known to 
increase with increasing age [56] and have an inverse 
correlation with Fas-induced apoptosis [57]. 
 
In the immune system, Fas and FasL are involved in 
down-regulation of immune reactions as well as in T cell-
mediated cytotoxicity [58]. In cancer, malignant cells 
inhibit the expression of membrane-bound Fas and 
express FasL which triggers tumor-infiltrating lympho-
cyte apoptotic cell death [59]. In contrast to their 
membrane-bound forms, soluble sFas and sFasL exhibit 
different patterns. The levels of sFas and sFasL have 





































ent populations of normal subjects [60, 61] and subjects 
with breast cancer [62-64] and prostate cancer [65, 66].  
Similarly, serum cytochrome c has been measured as a 
marker of apoptotic cell death [19, 67] and in cancer [21, 
68-70]. In general, serum Fas was elevated in cancer 
patients while sFasL levels were elevated or reduced, 
depending on the cancer group. Interpretation of 
published results on serum cytochrome c are complicated 
by the recent observation that cytochrome c exists in a 
complex with leucine-rich alpha-2-glycoprotein-1 in 
serum which alters immunoreactivity [20]. Thus, it is not 
clear whether studies measuring cytochrome c directly in 
serum are quantifying a free (unbound) pool or a pool 
reflecting some combination of free and complexed 
cytochrome c. In the current study, levels of 500 ng/ml 
total cytochrome c were measured on average in the 
normal population, which is at least 10-fold higher then 


























































































In a study of 204 clinically defined normal subjects, 
serum levels of sFas increased while sFasL and total 
cytochrome c decreased with increasing subject age.  In 
addition, the age-related elevation of sFas was 
significantly higher, while total cytochrome c was 
significantly lower in males from their 40’s and 50’s 
onward. This is the first report describing the 
distribution of these multiple markers in a single, well-
defined normal population. The healthy normal group 
had extensive exclusion criteria to minimize 






































the  75th  percentile  (top  quartile),  25th  percentile  (bottom
quartile), and 50th percentile (median) respectively. The error


























were  stratified  by  stage  and  the  distribution  of  sFas  (a,  b),
sFasL (c, d) and cytochrome c (e, f) stratified by staging was 











layer  of  the  prostate  to  nearby  tissues.  Stage  IV  is 
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referred to as age-related diseases (e.g. - cardiovascular 
disease, cancer, diabetes, Alzheimer's, osteoporosis) can 
be considered as manifestations of fast aging [72]. 
Given the correlations observed between donor age and 
the apoptosis markers in the normal healthy group, the 
expansion of the study group to include age-related 
diseases (whose serum values would reflect fast aging) 
might be expected to broaden the differences in these 
serum markers. 
 
The observed shift in the balance to decreased apoptosis 
may contribute to age-associated increases in diseases 
characterized by failure of normal apoptosis (e.g. – 
cancer, arthritis, cardiovascular disease). Indeed, in both 
breast and prostate cancer, correlative data on serum 
sFas, sFasL and total cytochrome c that were consistent 
with a shift toward decreasing apoptosis were also 
observed in the current study. Finally, many 
observations indicate that women have a longer life 
expectancy than men, that mortality and morbidity are 
higher in men than in women and this gender difference 
is constant in cardiovascular disease, cancer and 
dementia [73]. The observed gender differences in 
apoptosis markers - higher sFas and reduced sFasL and 
total  cytochrome c – which are of indicative of 
dysregulated apoptosis would be consistent with the 




Subjects. Approval for the study protocol was acquired 
from the local institutional review board and informed 
consent was obtained from all patients. Sera from 
clinically defined normal patients were obtained from a 
commercial serum bank (SeraCare Life Sciences Inc., 
Oceanside, CA) as well as from the Johns Hopkins 
Bayview Medical Center General Clinical Research 
Center (JHBMC).  The JHBMC normal group was 
obtained from an existing serum bank using samples 
from which all patient identifiers were removed. For 
this study, inclusion criteria as a normal serum donor 
included measures within the normal range for fasting 
glucose (< 100 mg/dl), TSH (0.5 - 2.1 mIU/mL), BMI 
(20 - 25 kg/m
2) as well as a physical assessment by a 
physician. Exclusionary criteria included a previous 
history of hypertension, heart disease, diabetes mellitus, 
renal or hepatic dysfunction, cancer, or any chronic 
inflammatory condition (e.g., rheumatoid arthritis). Sera 
from a group of 104 cancer subjects consisting of 66 
females with breast cancer and 38 males with prostate 
cancer were obtained from a serum repository. Blood 
was drawn at time of diagnosis, prior to initiation of 
treatment.  
Serum biochemical measures. Blood samples were 
drawn in the morning after an overnight fast. Serum 
biochemical measurements included sFas and sFasL by 
sandwich enzyme immunoassay technique (R&D, 
Systems, Minneapolis, MN). The assay performance 
characteristics in the laboratory for sFas were a 
sensitivity of 22.4 pg/ml, an intra-assay coefficient of 
variance of 2.48% and an inter-assay coefficient of 
variance of 6.06% and for sFasL were a sensitivity of 
7.2 pg/ml, an intra-assay coefficient of variance of 
3.64% and an inter-assay coefficient of variance of 
6.87%. 
 
Total cytochrome c assay. Cytochrome c protein stan-
dard (equine heart) was obtained from EMD Chemicals 
(Gibbstown, NJ). A mouse monoclonal anti-cytochrome 
c unconjugated antibody was obtained from Invitrogen 
(Carlsbad, CA). Goat anti-mouse IgG conjugated to 
horseradish peroxidase was obtained from Kirkgaard & 
Perry (Gaithersburg, MD). NuPAGE 4-12 % Bis –Tris 
1.5 mm X 15 well polyacrylamide gels, NuPAGE 
antioxidant and See blue pre-stained standards were 
obtained from Invitrogen. Super Signal West Dura 
Extended Duration Substrate was obtained from 
Thermo Fisher Scientific Inc. (Waltham, MA). 
 
Serum samples, after being reduced with 10 mM DTT 
and diluted in gel sample buffer (1:10), were resolved 
by Nu PAGE 4-12% Bis Tris gel.  8µl of diluted and 
reduced sample was loaded onto the gel for each 
sample. Purified equine heart cytochrome c was used to 
generate a standard curve at 20, 10, 5, 2, and 1 ng/well. 
After electrophoresis, samples were transferred to 
nitrocellulose membrane following standard conditions. 
After a 1-h incubation in blocking solution (TBS-
Tween+5% non fat powdered milk) at room 
temperature on rotary shaker, a mouse monoclonal anti-
cytochrome c antibody was added at a dilution of 1: 
2000 and incubated over night at 4 c on a rotary shaker. 
The nitrocellulose membrane was washed in TBS-
Tween three times for 5 minutes each and then goat 
anti-mouse IgG conjugated to horseradish peroxidase 
diluted to 1:10,000 in TBS-Tween was added and 
incubated for 2 hrs at room temperature. Following 
removal of second antibody solution, the membrane was 
washed three times with TBS -Tween and exposed to 
the chemiluminiscent enzyme substrate for 5 minutes. 
Signals were captured, digitized and analyzed using a 
Kodak GEL Logic 2200 Imaging System (Carestream 
Health Inc., Rochester, NY). 
 
Statistical analysis. Comparisons between groups were 
performed conservatively using the Mann Whitney 
nonparametric test. The association of sFas, sFasL or 
cytochrome c with donor age was analyzed using the 
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All statistical calculations were carried out using 
GraphPad Prism version 5.00 for MacOS (GraphPad 
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